Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

  • ID: 3960480
  • Company Profile
  • 111 pages
  • Global Markets Direct
  • Mitsubishi Tanabe Pharma Corporation
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • Kringle Pharma, Inc.
  • M3 Biotechnology, Inc.
  • Molecular Partners AG
  • ViroMed Co., Ltd.
  • MORE
Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

The report ‘Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016’, provides an overview of the Mitsubishi Tanabe Pharma Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Mitsubishi Tanabe Pharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of Mitsubishi Tanabe Pharma Corporation
- The report provides overview of Mitsubishi Tanabe Pharma Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Mitsubishi Tanabe Pharma Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Mitsubishi Tanabe Pharma Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate Mitsubishi Tanabe Pharma Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mitsubishi Tanabe Pharma Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitsubishi Tanabe Pharma Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • Kringle Pharma, Inc.
  • M3 Biotechnology, Inc.
  • Molecular Partners AG
  • ViroMed Co., Ltd.
  • MORE
Introduction

Mitsubishi Tanabe Pharma Corporation Snapshot

Mitsubishi Tanabe Pharma Corporation Overview

Key Facts

Mitsubishi Tanabe Pharma Corporation - Research and Development Overview

Key Therapeutic Areas

Mitsubishi Tanabe Pharma Corporation - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Mitsubishi Tanabe Pharma Corporation - Pipeline Products Glance

Mitsubishi Tanabe Pharma Corporation - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Mitsubishi Tanabe Pharma Corporation - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Mitsubishi Tanabe Pharma Corporation - Early Stage Pipeline Products

IND/CTA Filed Products/Combination Treatment Modalities

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Mitsubishi Tanabe Pharma Corporation - Drug Profiles

(canagliflozin + teneligliptin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amiselimod hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avanafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bepotastine besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

canagliflozin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cariprazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edaravone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fingolimod hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GB-1057 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infliximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masilukast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIN-117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Inflammatory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Undisclosed Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-124 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-157 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-0814 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-3995 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-4580 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-7117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NU-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit S-Adenosyl-L-Homocysteine Hydrolase for Undisclosed Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-6932 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TA-3404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teneligliptin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valbenazine tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Y-320 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mitsubishi Tanabe Pharma Corporation - Pipeline Analysis

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Target

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Route of Administration

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Molecule Type

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action

Mitsubishi Tanabe Pharma Corporation - Dormant Projects

Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

AMG-899

AV-412

caldaret

carmoterol

coleneuramide

colestilan chloride

ecabet

edaravone

encenicline hydrochloride

fingolimod hydrochloride

immune globulin (human)

marimastat

masilukast

MP-136

MP-435

MT-7716

netoglitazone

sofigatran

TA-5493

TA-5538

TA-6666

TAK-128

telaprevir

Y-700

Mitsubishi Tanabe Pharma Corporation - Company Statement

Mitsubishi Tanabe Pharma Corporation - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

List of Tables

Mitsubishi Tanabe Pharma Corporation, Key Facts

Mitsubishi Tanabe Pharma Corporation - Pipeline by Indication, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2016

Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2016

Mitsubishi Tanabe Pharma Corporation - Combination Treatment Modalities in Pipeline, 2016

Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2016

Mitsubishi Tanabe Pharma Corporation - Partnered Products/ Combination Treatment Modalities, 2016

Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2016

Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016

Mitsubishi Tanabe Pharma Corporation - Pre-Registration, 2016

Mitsubishi Tanabe Pharma Corporation - Phase III, 2016

Mitsubishi Tanabe Pharma Corporation - Phase II, 2016

Mitsubishi Tanabe Pharma Corporation - Phase I, 2016

Mitsubishi Tanabe Pharma Corporation - IND/CTA Filed, 2016

Mitsubishi Tanabe Pharma Corporation - Preclinical, 2016

Mitsubishi Tanabe Pharma Corporation - Discovery, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline by Target, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action, 2016

Mitsubishi Tanabe Pharma Corporation - Dormant Developmental Projects,2016

Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products, 2016

Mitsubishi Tanabe Pharma Corporation, Other Locations

Mitsubishi Tanabe Pharma Corporation, Subsidiaries

List of Figures

Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Indication, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2016

Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2016

Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2016

Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Target, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2016

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Amgen Inc.
- AnGes MG, Inc.
- F-star Biotechnology Limited
- Kringle Pharma, Inc.
- M3 Biotechnology, Inc.
- Minerva Biotechnologies Corporation
- Molecular Partners AG
- ViroMed Co., Ltd.
- Yooyoung Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll